Perspectives in immunotherapy

Meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy)

Paolo A. Ascierto, James Brugarolas, Luigi Buonaguro, Lisa H. Butterfield, David Carbone, Bruno Daniele, Robert Ferris, Bernard A. Fox, Jérôme Galon, Cesare Gridelli, Howard L. Kaufman, Christopher A. Klebanoff, Ignacio Melero, Paul Nathan, Chrystal M. Paulos, Marco Ruella, Ryan Sullivan, Hassane Zarour, Igor Puzanov

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Immunotherapy represents the third important wave in the history of the systemic treatment of cancer after chemotherapy and targeted therapy and is now established as a potent and effective treatment option across several cancer types. The clinical success of anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4, first, and anti-programmed death (PD)-1/PD-ligand (L)1 agents in melanoma and other cancers a few years later, has encouraged increasing focus on the development of other immunotherapies (e.g. monoclonal antibodies with other immune targets, adoptive cell transfer, and vaccines), with over 3000 immuno-oncology trials ongoing, involving hundreds of research institutes across the globe. The potential use of these different immunotherapeutic options in various combinations with one another and with other treatment modalities is an area of particular promise. The third Immunotherapy Bridge meeting (29-30 November, 2017, Naples, Italy) focused on recent advances in immunotherapy across various cancer types and is summarised in this report.

Original languageEnglish
Article number69
JournalJournal for ImmunoTherapy of Cancer
Volume6
Issue number1
DOIs
Publication statusPublished - Jul 11 2018

Fingerprint

Immunotherapy
Italy
Neoplasms
CTLA-4 Antigen
Adoptive Transfer
Therapeutics
Melanoma
Vaccines
History
Monoclonal Antibodies
Ligands
Drug Therapy

Keywords

  • Adoptive cell transfer combination therapy
  • Biomarkers
  • Cancer vaccines
  • Checkpoint inhibitors
  • Immunotherapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

Perspectives in immunotherapy : Meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy). / Ascierto, Paolo A.; Brugarolas, James; Buonaguro, Luigi; Butterfield, Lisa H.; Carbone, David; Daniele, Bruno; Ferris, Robert; Fox, Bernard A.; Galon, Jérôme; Gridelli, Cesare; Kaufman, Howard L.; Klebanoff, Christopher A.; Melero, Ignacio; Nathan, Paul; Paulos, Chrystal M.; Ruella, Marco; Sullivan, Ryan; Zarour, Hassane; Puzanov, Igor.

In: Journal for ImmunoTherapy of Cancer, Vol. 6, No. 1, 69, 11.07.2018.

Research output: Contribution to journalReview article

Ascierto, PA, Brugarolas, J, Buonaguro, L, Butterfield, LH, Carbone, D, Daniele, B, Ferris, R, Fox, BA, Galon, J, Gridelli, C, Kaufman, HL, Klebanoff, CA, Melero, I, Nathan, P, Paulos, CM, Ruella, M, Sullivan, R, Zarour, H & Puzanov, I 2018, 'Perspectives in immunotherapy: Meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy)', Journal for ImmunoTherapy of Cancer, vol. 6, no. 1, 69. https://doi.org/10.1186/s40425-018-0377-z
Ascierto, Paolo A. ; Brugarolas, James ; Buonaguro, Luigi ; Butterfield, Lisa H. ; Carbone, David ; Daniele, Bruno ; Ferris, Robert ; Fox, Bernard A. ; Galon, Jérôme ; Gridelli, Cesare ; Kaufman, Howard L. ; Klebanoff, Christopher A. ; Melero, Ignacio ; Nathan, Paul ; Paulos, Chrystal M. ; Ruella, Marco ; Sullivan, Ryan ; Zarour, Hassane ; Puzanov, Igor. / Perspectives in immunotherapy : Meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy). In: Journal for ImmunoTherapy of Cancer. 2018 ; Vol. 6, No. 1.
@article{f9987ec6077b43c794f1d06358af9f2e,
title = "Perspectives in immunotherapy: Meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy)",
abstract = "Immunotherapy represents the third important wave in the history of the systemic treatment of cancer after chemotherapy and targeted therapy and is now established as a potent and effective treatment option across several cancer types. The clinical success of anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4, first, and anti-programmed death (PD)-1/PD-ligand (L)1 agents in melanoma and other cancers a few years later, has encouraged increasing focus on the development of other immunotherapies (e.g. monoclonal antibodies with other immune targets, adoptive cell transfer, and vaccines), with over 3000 immuno-oncology trials ongoing, involving hundreds of research institutes across the globe. The potential use of these different immunotherapeutic options in various combinations with one another and with other treatment modalities is an area of particular promise. The third Immunotherapy Bridge meeting (29-30 November, 2017, Naples, Italy) focused on recent advances in immunotherapy across various cancer types and is summarised in this report.",
keywords = "Adoptive cell transfer combination therapy, Biomarkers, Cancer vaccines, Checkpoint inhibitors, Immunotherapy",
author = "Ascierto, {Paolo A.} and James Brugarolas and Luigi Buonaguro and Butterfield, {Lisa H.} and David Carbone and Bruno Daniele and Robert Ferris and Fox, {Bernard A.} and J{\'e}r{\^o}me Galon and Cesare Gridelli and Kaufman, {Howard L.} and Klebanoff, {Christopher A.} and Ignacio Melero and Paul Nathan and Paulos, {Chrystal M.} and Marco Ruella and Ryan Sullivan and Hassane Zarour and Igor Puzanov",
year = "2018",
month = "7",
day = "11",
doi = "10.1186/s40425-018-0377-z",
language = "English",
volume = "6",
journal = "Journal for ImmunoTherapy of Cancer",
issn = "2051-1426",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Perspectives in immunotherapy

T2 - Meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy)

AU - Ascierto, Paolo A.

AU - Brugarolas, James

AU - Buonaguro, Luigi

AU - Butterfield, Lisa H.

AU - Carbone, David

AU - Daniele, Bruno

AU - Ferris, Robert

AU - Fox, Bernard A.

AU - Galon, Jérôme

AU - Gridelli, Cesare

AU - Kaufman, Howard L.

AU - Klebanoff, Christopher A.

AU - Melero, Ignacio

AU - Nathan, Paul

AU - Paulos, Chrystal M.

AU - Ruella, Marco

AU - Sullivan, Ryan

AU - Zarour, Hassane

AU - Puzanov, Igor

PY - 2018/7/11

Y1 - 2018/7/11

N2 - Immunotherapy represents the third important wave in the history of the systemic treatment of cancer after chemotherapy and targeted therapy and is now established as a potent and effective treatment option across several cancer types. The clinical success of anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4, first, and anti-programmed death (PD)-1/PD-ligand (L)1 agents in melanoma and other cancers a few years later, has encouraged increasing focus on the development of other immunotherapies (e.g. monoclonal antibodies with other immune targets, adoptive cell transfer, and vaccines), with over 3000 immuno-oncology trials ongoing, involving hundreds of research institutes across the globe. The potential use of these different immunotherapeutic options in various combinations with one another and with other treatment modalities is an area of particular promise. The third Immunotherapy Bridge meeting (29-30 November, 2017, Naples, Italy) focused on recent advances in immunotherapy across various cancer types and is summarised in this report.

AB - Immunotherapy represents the third important wave in the history of the systemic treatment of cancer after chemotherapy and targeted therapy and is now established as a potent and effective treatment option across several cancer types. The clinical success of anti-cytotoxic T-lymphocyte-associated antigen (CTLA)-4, first, and anti-programmed death (PD)-1/PD-ligand (L)1 agents in melanoma and other cancers a few years later, has encouraged increasing focus on the development of other immunotherapies (e.g. monoclonal antibodies with other immune targets, adoptive cell transfer, and vaccines), with over 3000 immuno-oncology trials ongoing, involving hundreds of research institutes across the globe. The potential use of these different immunotherapeutic options in various combinations with one another and with other treatment modalities is an area of particular promise. The third Immunotherapy Bridge meeting (29-30 November, 2017, Naples, Italy) focused on recent advances in immunotherapy across various cancer types and is summarised in this report.

KW - Adoptive cell transfer combination therapy

KW - Biomarkers

KW - Cancer vaccines

KW - Checkpoint inhibitors

KW - Immunotherapy

UR - http://www.scopus.com/inward/record.url?scp=85049861270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049861270&partnerID=8YFLogxK

U2 - 10.1186/s40425-018-0377-z

DO - 10.1186/s40425-018-0377-z

M3 - Review article

VL - 6

JO - Journal for ImmunoTherapy of Cancer

JF - Journal for ImmunoTherapy of Cancer

SN - 2051-1426

IS - 1

M1 - 69

ER -